Given the metabolic plasticity of PDAC, SIRT5’s role in regulating noncanonical metabolic pathways positions it as a promising therapeutic target, with its activation offering a potential strategy to suppress tumor growth and improve the efficacy of existing treatments. Here, SIRT5 is linked to neoplasm.